Profound Medical Corp.
PROFNasdaq
$6.85
↑ +1.0%Jul 17 close · end-of-day
Price
1Y↑ +19.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$248.6M
Enterprise Value
$202.8M
P/E
5.5
P/S
13.2
P/B
4.2
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$18.8M
Net Income (TTM)
-$38.9M
Free Cash Flow (TTM)
—
Gross Margin
71.1%
Operating Margin
-202.6%
Net Margin
-206.8%
ROE
-65.5%
ROIC
-220.8%
Debt / Equity
0.1
Net Cash
$45.8M
Return 1Y
+20.3%
Company profile
Profound Medical Corp. develops magnetic resonance guided ablation procedures for treatment of prostate disease, uterine fibroids, and palliative pain treatment. Its lead product TULSA-PRO system used for magnetic resonance imaging scanner in hospitals and treatment facilities.
- CEO
- Arun S. Menawat
- Sector
- Manufacturing
- Industry
- Medical Equipment
- Employees
- 150
- Headquarters
- Ontario
- Website
- profoundmedical.com
Earnings
PROF Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$5.3M↑ +103.6%
Diluted EPS$0.19↓ -47.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $7.2M | $10.7M | $16.1M |
| Gross profit | $4.3M | $7.0M | $11.4M |
| Operating income | -$28.7M | -$33.1M | -$41.3M |
| Net income | -$28.3M | -$27.8M | -$42.6M |
| Diluted EPS | $1.34 | $1.12 | $1.41 |
| Operating cash flow | -$22.6M | -$23.5M | -$38.2M |
| Free cash flow | — | — | -$38.4M |
| Gross margin | 59.9% | 65.9% | 70.8% |
| Operating margin | -398.0% | -309.6% | -256.3% |
| Net margin | -393.4% | -260.4% | -264.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.8M | $4.2M | $2.6M | $2.2M | $5.3M | $6.0M | $5.3M |
| Gross profit | $1.4M | $1.8M | $3.0M | $1.9M | $1.6M | $3.9M | $4.0M | $3.8M |
| Operating income | -$7.8M | -$9.0M | -$8.3M | -$11.2M | -$13.8M | -$8.9M | -$7.4M | -$8.0M |
| Net income | -$6.9M | -$9.4M | -$4.9M | -$10.7M | -$15.7M | -$8.0M | -$8.2M | -$7.1M |
| Diluted EPS | $0.28 | $0.38 | $0.19 | $0.36 | $0.52 | $0.26 | $0.27 | $0.19 |
| Operating cash flow | -$6.2M | -$6.8M | -$5.9M | -$8.3M | -$13.7M | -$9.6M | -$6.6M | -$8.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 63.6% | 63.1% | 70.9% | 70.7% | 73.2% | 74.3% | 66.8% | 71.8% |
| Operating margin | -351.2% | -317.7% | -199.8% | -426.0% | -624.4% | -168.5% | -123.3% | -150.3% |
| Net margin | -309.9% | -330.7% | -118.5% | -409.2% | -709.9% | -150.8% | -136.8% | -132.2% |
Company news
Jul 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.